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Abstract
Endothelin is a vasoconstricting peptide that plays a key role in vascular homeostasis, exerting its biologic effects via
two receptors, the endothelin receptor A (ETA) and endothelin receptor B (ETB). Activation of ETA and ETB has
opposing actions, in which hyperactive ETA is generally vasoconstrictive and pathologic. Selective ETA blockade has
been shown to be beneficial in renal injuries such as diabetic nephropathy and can improve proteinuria. Atrasentan is
a selective pharmacologic ETA blocker that preferentially inhibits ETA activation. In this study, we evaluated the
efficacy of ETA blockade by atrasentan in ameliorating proteinuria and kidney injury in murine adriamycin
nephropathy, a model of human focal segmental glomerulosclerosis. We found that ETA expression was unaltered
during the course of adriamycin nephropathy. Whether initiated prior to injury in a prevention protocol (5 mg/kg/day,
i.p.) or after injury onset in a therapeutic protocol (7 mg/kg or 20 mg/kg three times a week, i.p.), atrasentan did not
significantly affect the initiation and progression of adriamycin-induced albuminuria (as measured by urinary albumin-
to-creatinine ratios). Indices of glomerular damage were also not improved in atrasentan-treated groups, in either the
prevention or therapeutic protocols. Atrasentan also failed to improve kidney function as determined by serum
creatinine, histologic damage, and mRNA expression of numerous fibrosis-related genes such as collagen-I and
TGF-β1. Therefore, we conclude that selective blockade of ETA by atrasentan has no effect on preventing or
ameliorating proteinuria and kidney injury in adriamycin nephropathy.
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Introduction
Upregulation of endothelin signaling has been implicated in a
wide variety of chronic kidney diseases (CKD). Endothelins are
21-amino acid peptides that act as potent vasoconstrictors, and
there are three known isotypes (ET-1, ET-2, and ET-3). The
kidney is a major source of ET-1, with most cells in the kidney
capable of producing the pre-pro-endothelin-1 peptide that is
subsequently processed to the final 21-amino acid form [1].
Current evidence suggests important roles for ET-1 in
regulating proteinuria, systemic blood pressure, intraglomerular
pressures, and CKD progression [2].
Endothelins exert biologic effects via two receptors,
endothelin receptor A and endothelin receptor B (ETA and
ETB). Since ETA activation leads to vasoconstriction, it is
widely thought that ETA contributes to renal pathology.
Meanwhile, ETB activation may be protective, leading to nitric
oxide release and vasorelaxation [3]. As such, specific ETA
receptor inhibitors have been developed in an attempt to block
the pathologic activation of this receptor while sparing ETB
receptor signaling.
Atrasentan is a selective endothelin receptor inhibitor with a
1000 to 2000-fold greater affinity for ETA compared to ETB.
This selectivity has been exploited in experimental models, in
which atrasentan has been shown to inhibit various kidney
injuries [4]. For instance, atrasentan was capable of inhibiting
proteinuria, inflammation, and glomerular permeability, while
abrogating declining nephrin expression in experimental
diabetes in rodents [5]. Atrasentan could also ameliorate
hypertensive kidney disease with a magnitude comparable to
renin-angiotensin system (RAS) blockade [6]. Other
specifically-designed ETA inhibitors such as avosentan and
sitaxsentan were similarly protective in diabetic nephropathy
and 5/6 nephrectomy models [7-9].
Human trials have shown promise in treating kidney disease
as well. When added to the standard of care (RAS inhibitors) in
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diabetic patients, ETA blockade with either atrasentan or
avosentan was capable of reducing proteinuria, a key indicator
of renal injury [10-12]. However, adverse side effects, in
particular fluid retention, have limited the use of these agents in
the clinic.
In this study we attempted to further examine the role of
atrasentan in proteinuria and podocyte injury. To do this, we
utilized the adriamycin nephropathy model of proteinuria and
glomerular injury, which recapitulates the human disease of
focal segmental glomerulosclerosis (FSGS). In this model,
adriamycin administration causes glomerular damage and
increased urinary albumin excretion, followed by tubular
atrophy and dilation and ultimately renal fibrosis in mice [13].
We hypothesized that atrasentan can inhibit the development
of proteinuria in this model similar to the diabetic mouse model
and human trials. However, we found that atrasentan given
before the onset or after the initiation of kidney injury could not
prevent adriamycin-induced albuminuria and kidney injury,
indicating that atrasentan is not a viable treatment for
adriamycin nephropathy.
Materials and Methods
Animals and treatment protocol
All animal studies were performed in accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the NIH. The protocol was approved by
the Institutional Animal Care and Use Committee of the
University of Pittsburgh Medical Center. Male BALB/c mice (6
to 8-week old) were purchased from Harlan Laboratories
(Indianapolis, IN) and housed in the University of Pittsburgh
Medical Center animal facility. For the studies examining
endothelin-1 and its receptors, mice were subjected to a single
intravenous tail-vein injection of adriamycin (10 mg/kg;
doxorubicin hydrochloride; Sigma, St. Louis, MO), or saline
vehicle for controls. Urine was collected on the day of sacrifice,
with mice being euthanized 1, 3, or 5 weeks after adriamycin
injection, as indicated. Blood and kidney samples were also
obtained at time of sacrifice.
In the atrasentan experiments we utilized two different
protocols. In Protocol 1 (prevention protocol), mice were
treated with atrasentan (kindly provided by Abbott Laboratories,
Abbott Park, IL) (5 mg/kg, i.p.) daily starting the day prior to
adriamycin injection. Seven days after adriamycin injection,
mice were sacrificed and samples collected and were
compared to a control group that did not receive atrasentan. In
Protocol 2 (therapeutic protocol), mice were treated with
adriamycin as above, and at seven days after injection, urine
was collected and albuminuria assessed. Since adriamycin can
cause wide variations in levels of proteinuria, we placed mice
into three groups that all had a near-equivalent mean urinary
albumin excretion. This protocol ensured that each group was
roughly equivalent in terms of glomerular damage and
albuminuria, and prevented spurious data that might result from
heterogeneity in initial adriamycin-induced injury. The groups
were then randomized to one of three treatments arms: 1)
vehicle injections; 2) 7 mg/kg atrasentan injections; and 3) 20
mg/kg atrasentan injections. The injections were performed
three times weekly for the remainder of the experiment, and
were started on day 10. Urine was collected weekly, and
sacrifice of mice was performed 35 days after adriamycin
administration, and blood and kidney samples were collected.
In both Protocol 1 and 2 a corresponding control group that
received vehicle injections instead of adriamycin or atrasentan
was included for comparison.
Drug preparation
Adriamycin was prepared fresh on day of use at a
concentration of 1 mg/ml in saline. The drug was dissolved with
gentle agitation protected from light, and filtered through a 0.22
micron filter to establish sterility for injection. A 10 mg/kg dose
was used for all mice based on effects we have previously
described [14]. Atrasentan was initially dissolved in absolute
ethanol before dilution in 0.05M NaOH / 0.9% saline.
Atrasentan was sterile filtered before use, and delivered as a
dose of 5 mg/kg daily in Protocol 1, or as a dose of either 7
mg/kg or 20 mg/kg three times a week in Protocol 2.
Biochemical measurements
Serum and urine creatinine were measured using a kit from
Bioassay Systems (Hayward, CA). A kit from Bethyl
Laboratories (Montgomery, TX) was used to determine urinary
albumin excretion. Urine albumin was normalized to urine
creatinine (mg albumin / mg creatinine).
Western blots
Protein expression was analyzed by Western blot analysis as
described previously [15]. Briefly, total kidney homogenates
were prepared in radioimmunoprecipitation assay (RIPA) buffer
with protease inhibitor cocktails and protein levels determined
by using the BCA protein assay kit (Sigma Aldrich, St. Louis,
MO). Equivalent protein amounts were subjected to SDS-
PAGE and blotted onto nitrocellulose membranes. Blots were
subjected to overnight incubation with primary antibodies
followed by secondary antibody incubation for one hour and
detected with Supersignal West Pico substrate reagents
(Pierce, Rockford, IL). The primary antibodies used were as
follows: anti-nephrin (#2OR-NP002, Fitzgerald Industries,
Acton, MA), anti-α-smooth muscle actin (α-SMA) (A2547;
Sigma, St. Louis, MO), anti-actin (#MAB1501, Chemicon,
Billerica MA), and anti-α-tubulin (T9026) (Sigma).
Immunofluorescence staining
Frozen tissue sections (5 µm) were prepared from
embedded kidneys in optimal cutting temperature (OCT)
medium. After blocking for one hour, sections were incubated
overnight with anti-nephrin antibody (1:200 dilution, catalog
#2OR-NP-002, Fitzgerald Industries, Acton, MA) and anti-WT1
antibody (1:50 dilution, catalog #sc-192, Santa Cruz
Biotechnology, Dallas, TX). Sections were then incubated with
secondary antibodies conjugated to Cy3 and Cy2, respectively,
and imaged with an Olympus Fluoview 500 Confocal
Microscope. All images within an experiment were
photographed on the same day with identical confocal settings.
To determine the number of WT1-positive cells per glomeruli,
Atrasentan and Adriamycin Nephropathy
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positively staining cells were counted in 20 glomerular sections
from each animal and averaged.
Histology and glomerular injury scoring
Paraffin sections (3 µm) were stained with Masson’s
trichrome staining reagents from Sigma (St. Louis, MO)
according to kit instructions. Blinded gomerular scoring was
done by evaluating 20 glomeruli per animal. Scoring was
performed with a scale indicating the percentage of the total
area of an individual glomerulus that was damaged by
adriamycin. The scoring scale was as follows: 0 = no damage;
1 = 1-25% of glomerular area; 2 = 26-50%; 3 = 51-75%; and 4
= 76 to 100% (global damage).
Quantitative, real-time reverse transcriptase PCR (qRT-
PCR)
RNA was isolated from kidney homogenates using Trizol
reagent (Life Technologies, Grand Island, NY). After first strand
cDNA synthesis from equivalent starting RNA material for each
sample, qRT-PCR was performed using specific primers for
ETA, ETB, ET-1, collagen-I, fibronectin, TGF-β1, CTGF,
Snail1, and α-SMA using SYBR green reagents and a StepOne
PCR instrument from Life Technologies/Applied Biosystems
(Grand Island, NY), as described previously [16]. Primer
sequences are listed in Table S1. Cycles were run at 95°C for
15 seconds followed by annealing at 60°C for 60 seconds.
Statistics
All statistical comparisons were made using a one-way
ANOVA. In the event of non-normality of data ANOVA based
on ranks was performed. A Dunn’s post-test using pairwise
comparison was utilized to determine group differences. P <
0.05 was the threshold used for significance.
Results
ETA expression is unaffected in adriamycin
nephropathy
We first examined the effect of adriamycin administration on
renal expression of components of the endothelin system.
BALB/c mice were treated with 10 mg/kg adriamycin and
sacrificed at 1, 3, and 5 weeks. As shown in Figure 1A, ETA
receptor gene expression did not change throughout this time
course, while ETB had a significant, albeit small, increase in
gene expression at 1 week after adriamcyin administration
before returning to baseline (Figure 1B). On the other hand,
there was a large increase in ET-1 expression after adriamycin
administration, but not until 5 weeks after adriamycin injection
(Figure 1C). The increase in ET-1 suggested that ETA
inhibition could be a viable treatment for adriamycin-induced
kidney injury.
Atrasentan does not prevent proteinuria in adriamycin
nephropathy
We initially sought to determine the effects of atrasentan in
preventing the development of adriamycin nephropathy. By
using a prevention protocol (Figure 2A), atrasentan was given
to mice starting one day prior to adriamycin administration, at a
dose of 5 mg/kg mouse body weight daily. Mice were sacrificed
7 days after adriamycin injection, and urine was collected at the
start (day -1) and end of the experiment (day 7). There was no
difference in albuminuria at the start of the experiment (control
group = 0.201 ± 0.013 mg/mg creatinine; adriamycin group =
0.889 ± 0.673; adriamycin/atrasentan group = 0.269 ± 0.656).
In agreement with previous data, albuminuria was increased
after adriamycin treatment compared to normal controls (Figure
2B) [14]. However, there was no significant difference between
adriamycin-treated mice and adriamycin/atrasentan-treated
mice (n=12 for each group). Serum creatinine also did not differ
after adriamcyin with or without atrasentan (Figure 2C).
Figure 1.  Renal expression of the endothelin system components in adriamycin nephropathy.  Mice were treated with saline
or adriamycin (10 mg/kg) and sacrificed at the indicated time points. RNA was extracted from harvested kidneys and subjected to
quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR) analysis. The mRNA expression of the ETA
receptor (A), ETB receptor (B), and ET-1 (C) is presented. *P < 0.05 compared to 3 week and 5 week adriamycin groups. †P < 0.05
compared to saline controls.
doi: 10.1371/journal.pone.0079963.g001
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Figure 2.  Atrasentan does not prevent proteinuria in adriamycin nephropathy.  (A) In this prevention protocol, treatment with
atrasentan (5 mg/kg i.p., open triangles) was started one day prior to administration of a single dose of adriamycin (ADR, 10 mg/kg
i.v., closed triangle) or saline vehicle (Ctrl). Mice were sacrificed 7 days after adriamycin injection, at which time urine, blood, and
tissues were collected. (B) Urinary albumin excretion was determined for each mouse and normalized for urinary creatinine
excretion (n=11 for Ctrl group, n=12 for ADR group, and n=12 for ADR / ATR group). *P < 0.05 compared to the Ctrl group. (C)
Serum creatinine is shown for all mice in a similar fashion. There was no significant difference between groups at this early time
point.
doi: 10.1371/journal.pone.0079963.g002
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Atrasentan is unable to prevent podocyte dysfunction
Since podocyte dysfunction is a key feature of adriamcyin
nephropathy, we next examined whether there is an effect of
atrasentan on podocytes in our model. To do this, we
examined nephrin and WT1 (Wilms tumor 1) levels. Nephrin
protein levels did not change significantly when atrasentan was
added to adriamycin treatment in mice when examined by
western blot analyses (Figure 3A). Similarly, when counting
WT1 positive cells per glomerular section, we detected a
decrease in WT1 expression after adriamycin, but no
significant difference when atrasentan was added to
adriamycin (Figure 3B). Immunofluorescence staining also
showed that control mice had a linear pattern of nephrin
staining along the slit diaphragm, which indicates normal
nephrin distribution and podocyte function. However, the
adriamycin-treated mice had non-linear granular staining which
was not improved with the addition of atrasentan. This non-
linear staining indicates aberrant nephrin distribution and
podocyte dysfunction. Similarly, while control mice had
abundant WT-1 nuclear staining, this staining was decreased in
adriamycin mice and was not significantly different in the
adriamycin / atrasentan mice (Figure 3, C-E). These results
indicated that atrasentan was incapable of preventing initial
podocyte injury when exposed to adriamycin in vivo.
Atrasentan fails to ameliorate established proteinuria
and podocyte injury
Given that ET-1 is induced at a late time point in this model
(Figure 1), we next tested whether blockade of ETA by
atrasentan at late time points could ameliorate proteinuria and
slow the progression to CKD. Therefore, we designed a
therapeutic protocol (Figure 4A). Mice were subjected to
treatment with saline or adriamycin, with urine collected at 7
days. Mice were then randomized into groups such that mean
albuminuria was similar between each group at 7 days after
adriamycin injection (Figure 4B). This randomization based on
albuminuria level was used because of a wide inter-animal
variability in this model [13]. We utilized two different doses of
atrasentan, given as 7 mg/kg or 20 mg/kg three times weekly
starting on day 10 after adriamycin. As shown in Figure 4, C
through E, there was no improvement of proteinuria with either
dose of atrasentan when compared to vehicle controls at 21,
28, or 35 days after adriamycin injection. These conclusions
were unchanged even if we eliminated the few mice exhibiting
markedly higher albuminuria than their counterparts (data not
shown). Similarly, serum creatinine was unaffected by
atrasentan, although at this time point the creatinine did not
increase after adriamycin (Figure 4F). When podocyte-specific
markers were assessed, there were no differences in overall
nephrin expression in atrasentan-treated mice (at either dose)
compared to vehicle controls (Figure 5, A-D). In terms of WT1-
positive cells there was again no significant difference in
adriamycin-treated mice given either dose of atrasentan
(Figure 5G). This remained true even if the WT-1 positive cells
were normalized to the total number of nuclei per glomerular
section (data not shown). The immunofluorescence staining for
nephrin and WT1 was not improved by atrasentan (Figure 5H).
Finally, when we assessed glomerular damage histologically,
we also did not find any overall improvement when comparing
adriamcyin-treated mice with mice that also received
atrasentan (Figure 5, I-J). Collectively, we were unable to
detect any improvement in glomerular damage parameters with
atrasentan.
Atrasentan does not improve fibrotic lesions in
adriamycin nephropathy
Although glomerular damage and albuminuria are the
primary outcomes of our study, we elected to examine
indicators of chronic renal injury as a secondary endpoint. At
35 days, histology was examined with Masson’s trichrome
staining, which stains collagen deposition with blue color.
There was an increase in damaged tubules and collagen
deposition in adriamycin-treated mice compared to normal
controls (Figure 6, A versus C). Although there was some
variability between animals, there was no overall difference in
histological damage between vehicle and atrasentan groups
(Figure 6, G-H). In agreement with these results, the
expression of α-smooth muscle actin (α-SMA), a marker of
myofibroblast activation, was not reduced by atrasentan
treatment (Figure 6I).
Utilizing quantitative RT-PCR (qRT-PCR), we further
examined the expression of numerous genes such as collagen-
I, TGF-β1, fibronectin, α-SMA, connective tissue growth factor
(CTGF), and Snail1, which are all implicated in renal fibrosis
through extracellular matrix accumulation, epithelial-
mesenchymal transition, or fibroblast activation [17]. As shown
in Figure 6J, atrasentan did not affect renal mRNA expression
of collagen-I and TGF-β1 at 5 weeks after adriamycin injection.
Similarly, atrasentan also did not inhibit the mRNA expression
of other fibrosis-related genes including fibronectin, α-SMA,
CTGF and Snail1 (data not shown).
Discussion
Atrasentan has been shown to reduce albuminuria in a
variety of experimental kidney injuries, presumably due to
blockade of ET-1 signaling through the pathologic ETA
receptor. Atrasentan has been shown to reduce urinary protein
excretion in rodent experimental models of both hypertension
and diabetes [5,18,19]. These experimental findings are
accompanied by human studies which also revealed reduced
albuminuria in diabetic patients receiving atrasentan [10].
Based on these observations, we originally hypothesized that
atrasentan would prevent the albuminuria associated with
adriamycin nephropathy, a model for human FSGS. To our
surprise, we were unable to detect any improvement in
albumin-to-creatinine ratios in this model when atrasentan was
delivered daily prior to the start of injury in a 7-day acute
prevention model. Similarly, there was no improvement in
albuminuria when atrasentan was given after the onset of injury
in a chronic 35-day protocol. Consistent with these findings,
there was no effect on histologic glomerular damage and
overall nephrin and WT1 expression in glomerular podocytes
by atrasentan in vivo. In our chronic therapeutic protocol, we
were also unable to detect any improvement in serum
Atrasentan and Adriamycin Nephropathy
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creatinine, histologic damage, or expression of fibrosis-related
genes.
The reasons for the lack of efficacy of atrasentan in our
adriamycin model may be complex. First, we were unable to
detect a difference in ETA receptor expression at 1, 3, or 5
weeks after adriamycin injection (Figure 1A), suggesting that
ETA activation is not a primary mechanism leading to
proteinuria in this model. Furthermore, there was no change in
ET-1 expression until very late in the course of disease, 5
weeks after adriamycin injection (Figure 1C). The lack of an
increase in either ET-1 or ETA receptor prior to the 5 week
timepoint could explain why an ETA-specific receptor inhibitor
delivered during this time was ineffective in preventing
albuminuria. However, we cannot completely exclude the
possibility that atrasentan might be effective in preventing
albuminuria after 5 weeks in this model.
Second, in terms of glomerular hemodynamics, ETA receptor
activation is purported to lead to altered afferent and efferent
Figure 3.  Podocyte injury is not attenuated by atrasentan in the prevention protocol.  Kidneys from the mice treated in Figure
2 were assessed for podocyte markers. (A) Western blot showing no overall change in nephrin levels from whole kidney
homogenates. Densitometry was normalized to actin as a loading control. (B) WT1 positive nuclei were counted in 20 glomerular
sections for each mouse (n=4) after immunofluorescence staining. *P < 0.05 compared to control. (C) Normal glomerular
immunofluorescence staining for nephrin (red) and WT1 (green). Note the linear nephrin staining (white arrow) and abundant WT1-
positive nuclei (yellow arrowheads). Scale bar equals 20 μm. (D) Representative micrograph showing the glomerulus from a mouse
treated with adriamycin (without atrasentan) and sacrificed at 7 days. Note that the nephrin staining is not uniformly linear and
appears speckled in numerous areas (white arrows) and is completely disrupted in other areas (asterisk). There is also a decrease
in WT1-positive nuclei (yellow arrowhead). (E) Glomerulus from an adriamycin-treated mouse that has been cotreated with
atrasentan as per the protocol in Figure 2A, showing similar losses of linear nephrin staining (white arrow) as well as complete
disruption of nephrin (asterisk) and similar reductions in WT-1 nuclei (yellow arrow).
doi: 10.1371/journal.pone.0079963.g003
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Figure 4.  Atrasentan does not ameliorate established proteinuria.  (A) In this therapeutic protocol, mice were first treated with
adriamycin on day 0 (10 mg/kg, closed triangle). After evaluation of albuminuria on day 7, mice were randomized into groups as
described in Materials and Methods to receive vehicle (ADR, n=6) or atrasentan at either 7 mg/kg (ADR/ATR 7, n=6) or 20 mg/kg
(ADR/ATR 20, n=5) which are designated as open triangles. Atrasentan was started on day 10 and given three times weekly until
sacrifice at 35 days. Control mice (Ctrl) that did not receive any adriamycin or atrasentan were also included. (B) Albuminuria at 7
days post-adriamycin. Each dot represents an individual mouse. Note that the mice are grouped such that similar levels of albumin
excretion were included in each arm of the study. Albuminuria was then measured at day 21 (C), day 28 (D), and day 35 (E). (F)
Serum creatinine was also assessed at 35 days. *P < 0.05 compared to control group only.
doi: 10.1371/journal.pone.0079963.g004
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Figure 5.  Atrasentan does not ameliorate established podocyte injury in adriamycin nephropathy.  Mice were treated as in
Figure 4A. (A, B) qRT-PCR analysis showed nephrin (A) and WT1 (B) mRNA expression. ADR, adriamycin alone; ADR/ATR7,
adriamycin-treated mice that also received atrasentan at 7 mg/kg; ADR/ATR20, adriamycin-treated mice that also received
atrasentan at 20 mg/kg. (C-F) Western blots and densitometry for nephrin expression in different groups as indicated. (C and E)
Atrasentan at 7 mg/kg; (D and F) Atrasentan at 20 mg/kg. (G) WT1-positive nuclei in 20 glomerular sections from each animal (n=3
for each group) were counted as in Figure 3. *P < 0.05 compared to control group only. (H) Representative glomerulus from mouse
treated with adriamycin and sacrificed at 35 days (left panel). Atrasentan at a dose of 7 mg/kg (middle panel) or 20 mg/kg (right
panel) did not improve the loss of linear staining for nephrin (white arrows), the areas of complete nephrin disruption (asterisk), or
the decrease in WT1-positive nuclei (yellow arrowheads). (I) Histologic scoring of 20 glomeruli per animal (n=4 for Ctrl group and
n=5 for all other groups) reveals no difference when atrasentan is added to adriamycin treatment. * P < 0.05 compared to control
group only. (J) Representative images of glomeruli from Ctrl and treatment groups, as indicated. Note a lack of improvement in
glomerular histology with atrasentan treatment. Scale bar equal 50 μm.
doi: 10.1371/journal.pone.0079963.g005
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arteriolar vasoconstriction [1,20]. These effects would affect
intraglomerular pressures and could lead to glomerular
hyperfiltration, which in turn could alter urinary albumin
excretion and cause glomerular injury. Glomerular
hyperfiltration does occur in subtotal renal ablation and diabetic
nephropathy [21,22], and atrasentan is indeed capable of
ameliorating injury in these models [8,9]. However, it is unclear
if there is really increased intraglomerular pressures in
adriamycin nephropathy, as earlier studies utilizing intricate
single nephron micropuncture techniques have shown that
adriamycin does not lead to significant hyperfiltration in rat
glomeruli in vivo [23]. As such, there would be no benefit for
atrasentan in improving intraglomerular pressures.
Other pathologic mechanisms for ET-1 must also be
considered. It has been proposed that podocyte cytoskeletal
disruption and endothelin activity are related events [24]. Our
study was not targeted at identifying such cytoskeletal
rearrangements, which would require specialized imaging
techniques. However, nephrin is a common marker of podocyte
injury and slit-diaphragm integrity. We were able to measure
this key protein and could not find any differences by several
techniques (Western blotting, qRT-PCR and immunostaining).
In addition, we demonstrated that levels of WT1, which is
normally expressed by podocytes but is downregulated in
injury, could not be sustained with the use of atrasentan,
suggesting that atrasentan was not able to ameliorate podocyte
dysfunction in our model. ET-1 is also thought to play a role in
the profibrotic response, particularly in upregulation of TGF-β
and other fibrosis-related genes [25]. We attempted to assess
expression of these genes, but did not find a significant
Figure 6.  Atrasentan does not affect morphologic injury and fibrogenic gene expression in adriamycin
nephropathy.  Masson’s trichrome staining was performed to determine levels of histologic injury in the mice at 35 days after
adriamycin injection. A saline-treated control that received neither adriamycin nor atrasentan is shown in Panel A with enlargement
of the boxed area in Panel B. Scale bar equals 100 μm in each figure. Histology from a mouse treated with adriamycin is shown in
Panel C with corresponding enlargement in D. Adriamycin with atrasentan at 7 mg/kg is shown in Panel E with enlargement in F.
Adriamycin with atrasentan at 20 mg/kg is shown in Panel G with enlargement in H. In Panel I, Western blot for α-smooth muscle
actin (α-SMA) is shown for different groups as indicated with α-tubulin as a loading control. In Panel J, qRT-PCR was performed for
assessing mRNA expression of collagen-I and TGF-β1. * P < 0.05 for ADR / ATR20 compared to saline Ctrl.
doi: 10.1371/journal.pone.0079963.g006
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difference between the vehicle and atrasentan groups at 35
days after adriamycin injection.
A potential concern is the dosing regimen we utilized for
atrasentan. Numerous studies utilized a dose of 5 mg/kg/day in
diabetic nephropathy [5], hypertensive glomerular injury [18],
congestive heart failure [26], and hypertension [27]. This is the
same dose utilized in our acute prevention protocol. For our
chronic studies we utilized either of two doses of atrasentan (7
mg/kg or 20 mg/kg) given three times weekly (cumulative
weekly doses of 21 mg/kg or 60 mg/kg, respectively), which
provided similar doses to a chronic protocol from a previous
report in which mice were given 5 mg/kg/day for 5 days each
week (cumulative dose of 25 mg/kg per week) [27]. While the
cumulative weekly doses are similar or even higher in our
study, we must acknowledge that the thrice weekly atrasentan
dose may have different results compared to a lower dose
given 5 times per week in these experiments. It should be
noted that our initial 7-day experiment did include a daily
dosing regimen with an adequate dose of atrsesntan that was
initiated before the onset of adriamycin injury. The result from
the shorter experiment in the prevention protocol was still
negative, suggesting lack of effect of atrasentan in this model.
Of note, our use of intraperitoneal (i.p.) injections is another
difference from earlier studies which predominantly utilized oral
atrasentan. Previous studies with atrasentan in rats revealed
approximately 35% bioavailability of oral atrasentan with
biological effects persisting to at least 24 hours [4]. While we
could not find precise pharmacokinetic data for i.p. doses, it
was reasonable to assume blood concentrations and duration
of effect of the drug at least as high as the oral route. Further,
i.p. dosing of atrasentan has been utilized by other
investigators [28]. Nonetheless, we must acknowledge this as a
difference between our paper and some prior studies that may
have affected our results.
In our chronic 35-day experiment, we elected to start
atrasentan injections after the initiation of adriamycin injury for
two reasons. First, this is similar to the clinical situation in
which patients with established renal injury receive a
medication to ameliorate disease. Second, ET-1 induction is a
late event in this model (Figure 1). In addition, this therapeutic
protocol allowed us to randomize mice into homogenous
groups based on their urinary albumin excretion at 7 days after
adriamycin injection, as proteinuria and renal damage display a
wide inter-animal variability in this model [13]. We believed that
this was a way to reduce statistical heterogeneity caused by
variations in albuminuria, akin to the use of inclusion criteria in
clinical trials. In spite of this, we were still unable to find any
significant albuminuria differences between groups.
In conclusion, atrasentan in our experimental protocol was
incapable of ameliorating albuminuria and podocyte injury
associated with adriamycin nephropathy, a model of human
FSGS. The causes for this may be related to the characteristic
features of this particular model of proteinuric kidney disease,
in which ETA expression is unaltered. Our results suggest that
blockade of ETA signaling by atrasentan may not be effective
in a subset of chronic kidney diseases wherein activation of the
endothelin system is not a primary cause of proteinuria and
kidney damage.
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